QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:ONTX

Onconova Therapeutics (ONTX) Stock Price, News & Analysis

$1.01
+0.04 (+4.12%)
(As of 04:38 PM ET)
Today's Range
$0.99
$1.10
50-Day Range
$0.67
$0.97
52-Week Range
$0.55
$1.45
Volume
208,380 shs
Average Volume
76,750 shs
Market Capitalization
$21.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Onconova Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
968.1% Upside
$11.00 Price Target
Short Interest
Healthy
0.10% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Onconova Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.94) to ($0.72) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.37 out of 5 stars

Medical Sector

507th out of 938 stocks

Pharmaceutical Preparations Industry

240th out of 433 stocks

ONTX stock logo

About Onconova Therapeutics Stock (NASDAQ:ONTX)

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

ONTX Stock Price History

ONTX Stock News Headlines

A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
Onconova Therapeutics Inc (ONTX)
Onconova Therapeutics, Inc. (ONTX)
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
See More Headlines
Receive ONTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
3/28/2024
Next Earnings (Estimated)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ONTX
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$11.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+989.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-18,960,000.00
Net Margins
-8,930.97%
Pretax Margin
-8,930.97%

Debt

Sales & Book Value

Annual Sales
$230,000.00
Book Value
$1.35 per share

Miscellaneous

Free Float
20,310,000
Market Cap
$21.21 million
Optionable
Optionable
Beta
1.34
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

ONTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Onconova Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ONTX shares.
View ONTX analyst ratings
or view top-rated stocks.

What is Onconova Therapeutics' stock price target for 2024?

1 brokers have issued 1-year price targets for Onconova Therapeutics' shares. Their ONTX share price targets range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 968.1% from the stock's current price.
View analysts price targets for ONTX
or view top-rated stocks among Wall Street analysts.

How have ONTX shares performed in 2024?

Onconova Therapeutics' stock was trading at $0.7456 at the beginning of the year. Since then, ONTX stock has increased by 38.1% and is now trading at $1.0299.
View the best growth stocks for 2024 here
.

Are investors shorting Onconova Therapeutics?

Onconova Therapeutics saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 20,700 shares, a decrease of 58.8% from the February 29th total of 50,300 shares. Based on an average daily trading volume, of 75,900 shares, the days-to-cover ratio is currently 0.3 days.
View Onconova Therapeutics' Short Interest
.

When is Onconova Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our ONTX earnings forecast
.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics, Inc. (NASDAQ:ONTX) posted its earnings results on Thursday, November, 11th. The biopharmaceutical company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.11. The biopharmaceutical company had revenue of $0.06 million for the quarter, compared to analysts' expectations of $0.06 million. Onconova Therapeutics had a negative net margin of 8,930.97% and a negative trailing twelve-month return on equity of 95.43%. During the same quarter in the prior year, the firm posted ($0.45) EPS.

When did Onconova Therapeutics' stock split?

Onconova Therapeutics's stock reverse split on the morning of Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Onconova Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM).

Who are Onconova Therapeutics' major shareholders?

Onconova Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Abraham N Oler, James J Marino and Steven M Fruchtman.
View institutional ownership trends
.

How do I buy shares of Onconova Therapeutics?

Shares of ONTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ONTX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners